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Abstract
Background: Configuring high quality care for the rapidly increasing number of people with type 2 diabetes (T2D) is a major
challenge worldwide for both providers and commissioners. In the UK, about two thirds of people with T2D are managed
entirely in primary care, with wide variation in management strategies and achievement of targets. Pay for performance,
introduced in 2004, initially resulted in improvements but disparities exist in ethnic minorities and the improvements are
levelling off. Community based, intermediate care clinics for diabetes (ICCDs) were considered one solution and are
functioning across the UK. However, there is no randomised trial evidence for the effectiveness of such clinics.
Trial Design, Methods and Findings: This is a cluster-randomised trial, involving 3 primary care trusts, with 49 general
practices randomised to usual care (n = 25) or intervention (ICCDs; n = 24). All eligible adult patients with T2D were invited;
1997 were recruited and 1280 followed-up after 18-months intervention. Primary outcome: achievement of all three of the
NICE targets [(HbA1c#7.0%/53 mmol/mol; Blood Pressure ,140/80 mmHg; cholesterol ,154 mg/dl (4 mmol/l)]. Primary
outcome was achieved in 14.3% in the intervention arm vs. 9.3% in the control arm (p = 0.059 after adjustment for
covariates). The odds ratio (95% CI) for achieving primary outcome in the intervention group was 1.56 (0.98, 2.49). Primary
care and community clinic costs were significantly higher in the intervention group, but there were no significant
differences in hospital costs or overall healthcare costs. An incremental cost-effectiveness ratio (ICER) of +£7,778 per QALY
gained, indicated ICCD was marginally more expensive at producing health gain.
Conclusions: Intermediate care clinics can contribute to improving target achievement in patients with diabetes. Further
work is needed to investigate the optimal scale and organisational structure of ICCD services and whether, over time, their
role may change as skill levels in primary care increase.
Trial Registration: ClinicalTrials.gov NCT00945204; National Research Register (NRR) M0014178167.
Citation: Wilson A, O’Hare JP, Hardy A, Raymond N, Szczepura A, et al. (2014) Evaluation of the Clinical and Cost Effectiveness of Intermediate Care Clinics for
Diabetes (ICCD): A Multicentre Cluster Randomised Controlled Trial. PLoS ONE 9(4): e93964. doi:10.1371/journal.pone.0093964
Editor: Stephen L. Atkin, Postgraduate Medical Institute & Hull York Medical School, University of Hull, United Kingdom
Received August 16, 2013; Accepted March 8, 2014; Published April 15, 2014
Copyright:  2014 Wilson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study is funded by National Institute for Health Research (NIHR) - Health Services and Delivery Research (HS&DR) stream (previously known as NIHR
SDO). This is a UK government funding (publicly funded) body. Project number: SDO/110/2005; Initial service for support costs was provided by Department of
health.NHS Leicester City, Thames Valley Diabetes Research Network (TVDRN), West Midlands South Comprehensive Local Research Network (CLRN), Primary Care
Research Network (PCRN) and DIERT charity provided additional support for the successful completion of the study. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript apart from critically reviewing the grant application prior to funding.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: aw7@leicester.ac.uk (AW); p.saravanan@warwick.ac.uk (PS)
. These authors contributed equally to this work.
" Membership of the ICCD trial group is provided in the Acknowledgments.
Introduction
The burden of diabetes is increasing rapidly across the world,
including low and middle-income countries [1]. More than 370
million people live with diabetes world-wide and 90% of them
have type 2 diabetes (T2D). Nearly 5 million people died due to
diabetes in 2012 alone and 50% of these deaths happened in
people under the age of 60 years [1]. In the United Kingdom
(UK), cardiovascular mortality in middle-aged people (40–65 years
of age) is 3 times higher if they have diabetes, despite apparent
improvement in their risk factors [2]. Among the non-communi-
cable diseases (NCDs), diabetes is the only NCD where the
projected morbidity and mortality is expected to increase [3].
Configuring high quality, evidence based and patient centred
services that can prevent higher cardiovascular mortality in all
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patients with diabetes is a major challenge and a perfect model has
been elusive for commissioners and providers of care [4].
The cost burden of T2D is also very high and more than 470
billion US dollars (USD) were spent in 2012 across the world, with
the majority of spending in high-income countries [1]. Over the
past two decades much emphasis has been placed on improving
the ways of delivering diabetes care, at reduced cost, whilst
maintaining or improving quality [5]. ‘‘Case finding’’ approaches
[6,7], ‘‘care closer to home’’ and ‘‘pay for performance’’ [4] are
such examples. Prior to the introduction of pay for performance as
a part of the Quality and Outcomes Framework (QoF) in 2004,
wide variation existed in the care of patients with T2D in primary
care including referral to specialist services [8]. Although this
incentive improved overall process and intermediate outcome
measures, significant disparity still exists in ethnic minorities [9].
The improvements are also levelling off, which may partly be due
to less challenging targets to secure the QoF points for pay for
performance [10].
Nationwide audit data for England 2009–10, showed that more
stringent targets for glycosylated hemoglobin (HbA1c#7.5%/
58.5 mmol/L), blood pressure (BP,140/80 mmHg) and total
cholesterol (,154 mg/dl/,4.0 mmol/l) were achieved in only
67%, 69% and 41% of people with T2D. Poor glycaemic control
was associated with younger age and social deprivation [4]. There
were still significant variations between general practices, with
practices in areas of high deprivation and serving populations with
higher proportions of ethnic minorities less likely to achieve
adequate levels of control, [9,11,12] as were practices with lower
levels of organisation [13].
In an attempt to improve diabetes care and due to the
uncertainty over the cost-effectiveness of hospital based specialist
services, alternative services to support primary care have been
commissioned widely across the UK. These clinics are called
‘‘Intermediate Care Clinics for Diabetes’’ (ICCD). Typically these
are community based, multidisciplinary teams, working closely
with general practices. Recent evidence has suggested that the
most effective interventions include team changes and case
management [6]; it is anticipated that such new services may
deliver high quality care nearer to the patients, potentially at a
lower cost. In some instances, evaluations of such clinics have been
conducted [14–16], but none has been evaluated in a randomised
trial or been comprehensive enough to include both economic
alongside clinical evaluation. The objective of the current study is
to evaluate the clinical and cost effectiveness of the ICCDs based
in three primary care trusts (PCTs) in England in a cluster
randomised controlled trial. Our findings show that such clinics
may improve cardiovascular risk factors and provide care closer to
home without any increase in overall costs.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The study protocol was approved by Trent Multi-centre
Research Ethics Committee (REC 06/MRE04/41). Institutional
review boards (Leicester, Coventry and Nuneaton) provided
research governance approval at each site. All protocol amend-
ments were approved by the REC. The trial was registered before
participants were recruited in the National Research Register
[NIHR NRR id: M0014178167; 29th Oct 2007] and subsequently
in the international trial register [ClinicalTrials.gov: Identifier
NCT00945204; 23rd July 2009]. A detailed protocol has been
published elsewhere [17].
Study Design and Participants
The study design was a pragmatic two-arm cluster randomised
controlled trial, conducted in three English PCTs in the East and
West Midlands. All were in urban areas with a higher than
average prevalence of diabetes and serving ethnically diverse
populations. At each site, ICCD clinics operated for an 18-month
period, the first starting in September 2008. Practices recruited to
the study were randomised (in-house software) by the UK Clinical
Research Network (UKCRN) accredited Warwick Clinical Trials
Unit to either control (usual care) or intervention. The interven-
tion practices had access to ICCD clinics. Practices randomised to
control were reminded of local diabetes management guidelines
and continued to manage their patients, including hospital
referrals, in the usual manner. Recruitment of practices and
patients started between Jan 2008 and May 2009 and the baseline
assessment were completed between Oct 2009 and Jan 2010, in
the three centres. The follow up were completed between Aug
2010 and Sep 2011.
All general practices in participating PCTs were invited to take
part. Randomisation was undertaken by an independent clinical
trials unit after written agreement had been obtained. Randomisa-
tion was stratified by practice size and PCT to achieve balanced
intervention and control arms. Participants were adults aged 18
years or over, diagnosed with T2D, with no severe cognitive
impairment, no severe mental illness and not receiving terminal
care. Apart from large practices, where the number invited was
capped at 200, all eligible patients were approached by a letter
from their general practitioner (GP) enclosing the study informa-
tion sheet with reply cards. To enhance participation rates, GPs
and practice nurses were also asked to introduce eligible patients to
the study opportunistically when they attended for a consultation.
Figure 1. Key features of the intermediate care services.
doi:10.1371/journal.pone.0093964.g001
Intermediate Care Clinics for Diabetes
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Clinical and Cost Outcome Measures
The primary outcome measure (combined control) was the
proportion of participants reaching all three of the targets (HbA1c,
BP and total cholesterol) recommended in NICE guidelines
(National Institute for health and Clinical Excellence) for patients
with T2DM [18]. These targets were: BP,140/80 mmHg, total
cholesterol ,154 mg/dL (,4 mmol/l) and HbA1c,7.0%
(53 mmol/mol). For HbA1c, the guidelines recommend a
‘general’ target of 6.5% (48 mmol/mol), but with flexibility for
individual patients aimed to be between 6.5–7.5% (48–58 mmol/
mol); after discussion, the project steering group set the target at
7.0% (53 mmol/mol).
Secondary outcomes comprised the proportion of participants
reaching targets for individual risk factors (HbA1c, BP and total
cholesterol), plus magnitude of changes in these, and health related
quality of life (HRQoL) measured using the Euro-QoL 5-
dimensions (EQ-5D) questionnaire [19]. The incremental cost
effectiveness of the intervention was estimated.
Patient Assessment Procedures
An independent research nurse or research assistant conducted
patient assessments using standard operating procedures after
obtaining written informed consent. Detailed history including
demographic data was collected at baseline. Assessments took
place throughout the day and most were conducted in the patients’
primary care practices. Patients were also offered evening
appointments at more convenient central locations. Baseline
examinations included BP using an average of three readings
from an automated sphygmomanometer, height and weight (BMI)
and self-reported smoking. Assays for cholesterol and HbA1c were
sent to the laboratory normally used by the practice and reported
in the same way as other samples from the practice. Blood tests
were not repeated if a result from the previous three months was
available from the GP records. All test results were made available
to the GP.
Emotional functioning using the ‘Problem Areas in Diabetes’
(PAID) questionnaire [20] continuity of care using the ‘Continuity
of Care Questionnaire’ [21]. The study included a qualitative
evaluation to be published separately.
Follow up assessments measured the same variables, and also
included information on resource use for the economic analysis. In
cases where patients did not attend follow up, we used the last
reading in the GP record for HbA1c, BP and cholesterol if these
had been assessed within three months of the planned follow up. It
was not feasible for researchers to be blinded to allocation, but all
outcome measures were objective and laboratory staff blind to
participants’ randomisation status.
The Intervention
Common features of ICCDs are listed in Figure 1. Clinics
worked closely with hospital-based specialist teams and commu-
nity services, including podiatry and dietetic services. Guidelines
Figure 2. Consort flow diagram of GP Practices and patients. Consort diagram of practices and patients recruited, numbers followed up and
included in analysis.
doi:10.1371/journal.pone.0093964.g002
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for referral to the ICCDs were common across all sites, and
included people with poorly controlled T2DM and poorly
controlled cardiovascular risk factors. Patients were managed by
the ICCD team until control of risk factors was achieved and then
referred back to primary care. In PCTs 1 and 2, only trial
participants were eligible to attend the clinics. In PCT 3, the
clinics were available to all patients in the intervention practices,
whether or not they agreed to participate in the trial, at the request
of commissioners.
Sample Size
To detect a difference of percentage well controlled from 50%
in control group to 60% in intervention group (alpha= 0.05
Power = 0.8) not allowing for clustering requires a sample size of
408 subjects in each arm. Using an Intra-cluster correlation
coefficient (ICC) of 0.047, and with 72 patients in each cluster, the
necessary sample size in each arm was 1,770, a total of 3,540. This
number is also adequate to detect a 10% difference in cholesterol
control (from 60% to 70%) and blood pressure control (from 60%
to 70%). Estimates of ICC for blood pressure and cholesterol were
taken from the UK Asian Diabetes Study (UKADS), a study of
care provision for people of South Asian ethnicity with diabetes
[22]. Assuming the ICC for our primary outcome (combined
control of HbA1c, blood pressure and cholesterol) was 0.05 and
achievement (from a baseline of 15–20% as suggested by local
audit data) was at 20% in the control arm and 30% in the
intervention arm, we would need a total of 2,848 patients. In
summary, the planned sample size was adequately powered to
detect differences in control of the three individual outcomes, and
well powered to detect differences in the combined outcome.
Although the study was successful in recruiting 49 practices (11,
13 and 25 in PCT 1, 2 and 3 respectively), recruitment of patients
was lower than expected. In total 1997 patients were recruited,
with an average of 42 per practice. When recruitment was
complete, we recalculated power assuming 75% follow up as
reported by UKADS [22]. This showed that the trial had 80%
power to detect a 12% difference in the primary outcome measure
(combined control). These revisions were reported to and agreed
by the funding body.
Analysis
Intention-to-treat (ITT) comparisons of the two groups were
conducted, with the primary dependent variable being the
proportion of patients achieving the primary outcome (combined
control). The main analysis included only patients with data at
both baseline and follow-up; patients with baseline assessment but
Table 1. Baseline characteristics.
Variable Control (n= 940) Intervention (n =1057) p-value
N (%) N (%)
PCT 1 242 (25.7) 431 (40.8) ,0.001
PCT 2 225 (23.9) 240 (22.7) 0.551
PCT 3 473 (50.3) 386 (36.5) ,0.001
Male 543 (58.1) 613 (58.4) 0.954
Smoking 118 (12.7) 116 (11.1) 0.305
Comorbidity
Hypertension 505 (55.6) 612 (59.1) 0.067
IHD 161 (17.7) 149 (14.4) 0.071
CVD 35 (3.85) 28 (2.72) 0.214
Heart failure 25 (2.75) 35 (3.38) 0.471
PVD 10 (1.10) 15 (1.45) 0.609
Renal failure 24 (2.63) 24 (2.31) 0.791
Ethnicity
White 614 (65.3) 554 (52.4) ,0.001
Asian 257 (27.3) 405 (38.3) ,0.001
Black 32 (3.40) 55 (5.20) 0.063
Other 37 (3.94) 43 (4.07) 0.972
Baseline assessment of outcome measures
Primary outcome (combined control) 81 (8.74) 116 (11.2) 0.09
Controlled HbA1c (,= 7.0%/53 mmol/mol) 497 (53.9) 536 (51.7) 0.357
Controlled blood pressure (,140/80 mmHg) 304 (32.8) 398 (38.3) ,0.001
Controlled cholesterol (,154 mg/dl/4 mmol/l) 442 (48.2) 519 (50.2) 0.377
Individual factors (mean/sd)
HbA1c 7.26 (1.24) 7.34 (1.40) 0.183
Systolic BP 137.4 (17.5) 136.9 (17.3) 0.525
Diastolic BP 80.8 (10.5) 79.5 (10.7) 0.007
Total Cholesterol 4.05 (1.04) 4.03 (1.13) 0.686
doi:10.1371/journal.pone.0093964.t001
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Table 2. Baseline characteristics for patients included in analysis.
Variable Control (n= 636) Intervention (n=591) p-value
N (%) N (%)
PCT 1 164 (25.8%) 166 (28.1%) 0.399
PCT 2 339 (53.3%) 237 (40.1%) ,0.001
PCT 3 133 (20.9%) 152 (25.7%) 0.054
Male 370 (58.2%) 347 (58.7%) 0.894
Smoking 77 (12.1%) 66 (11.2%) 0.672
Comorbidity
Hypertension 341 (53.6%) 335 (56.7%) 0.307
IHD 115 (14.9%) 95 (16.1%) 0.392
CVD 22 (3.46%) 15 (2.54%) 0.438
Heart failure 15 (2.36%) 17 (2.88%) 0.697
PVD 7 (1.10%) 9 (1.52%) 0.690
Renal failure 13 (2.04%) 12 (2.03%) 1.000
Ethnicity
White 365 (57.4%) 271 (45.9%) ,0.001
Asian 98 (15.4%) 202 (34.2%) ,0.001
Black 20 (3.14%) 33 (5.58%) 0.050
Other 20 (3.14%) 22 (3.72%) 0.690
Baseline assessment of outcome measures
Primary outcome (combined control) 61 (9.59%) 76 (12.9%) 0.084
Controlled HbA1c (,= 7.0%/53 mmol/mol) 347 (54.6%) 326 (55.2%) 0.878
Controlled blood pressure (,140/80 mmHg) 354 (55.7%) 324 (54.8%) 0.812
Controlled cholesterol (,154 mg/dl/4 mmol/l) 305 (48.0%) 308 (52.1%) 0.162
Individual factors (mean/sd)
HbA1c 7.22 (1.24) 7.18 (1.23) 0.470
Systolic BP 137.5 (17.3) 137.0 (18.0) 0.528
Diastolic BP 80.6 (10.0) 79.3 (10.7) 0.005
Total Cholesterol 4.05 (1.04) 3.99 (1.18) 0.231
doi:10.1371/journal.pone.0093964.t002
Table 3. Follow-up outcome measures (n = 1280).
Variable Control (n= 636) Intervention (n=644) p-value
N (%) N (%)
Primary outcome (combined control) 59 (9.3) 92 (14.3) 0.007
Secondary outcome measures: achieved targets
HbA1c (,= 7.0%/53 mmol/mol) 325 (51.1) 370 (57.5) 0.026
Blood pressure (,140/80 mmHg) 203 (32.0) 256 (39.8) 0.004
Cholesterol (,154 mg/dl/4 mmol/l) 351 (55.2) 397 (61.8) 0.022
Individual factors (mean/sd)
HbA1c 7.28 (1.36) 7.17(1.37) 0.150
Systolic Blood Pressure 138.0 (17.9) 136.9 (17.9) 0.272
Diastolic Blood Pressure 80.5 (10.2) 79.1 (10.7) 0.017
Total cholesterol 3.90 (1.11) 3.79 (1.01) 0.064
doi:10.1371/journal.pone.0093964.t003
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no evidence of further engagement with the study were excluded.
Wherever follow-up data was partially present but with some
missing values, those values were replaced where possible using
last observation carried forward (LOCF). The LOCF values
generated for the outcome variables were then studied to check
they did not result in measures at either extreme of the
distribution: these checks revealed that the distribution of the
LOCF values closely resembled those of the variables themselves.
The fact that some patients present at baseline were excluded from
the analysis introduces the possibility of bias.
Unadjusted chi-square test was used to compare baseline
characteristics for all the descriptive measures. Analyses used a
mixed effects logistic regression model, and adjusted for baseline
characteristics at both practice and individual level. The mixed
effects logistic regression model was constructed including GP
practice as a random effect. We included the baseline combined
control as a fixed effect plus additional fixed effects; age, gender,
ethnicity, smoking status, PCT, deprivation index [23], hyperten-
sion, ischaemic heart disease, cerebrovascular disease, heart
failure, peripheral vascular disease and renal failure. All variables
were retained in the model. Estimates, standard errors and p-value
for the intervention effect and other covariates were estimated,
along with odds ratios and 95% confidence intervals, adjusting for
potential confounding variables and allowing for the effect of the
cluster randomisation [24]. The intervention was tested at the 5%
(two-tailed) level. All statistical procedures were performed in the
R 2.13.0 statistical package, using the lmer function for mixed
effect models.
Further analyses examined secondary outcomes; individual
variables contributing to combined control, again adjusting for
confounders and allowing for the cluster randomisation. We
separately analysed the percentage of patients controlling HbA1c,
blood pressure (systolic and diastolic), and lipids. These variables
were also analysed as numerical measures and ICCs calculated.
This required a consideration of whether a normal approximation
was valid, using Q-Q plots in each case. Likelihood ratio tests were
performed.
Economic Evaluation
The within trial economic evaluation compared direct costs and
18-month outcomes of patients randomised to intervention versus
control. The primary perspective adopted was that of the NHS as
commissioner. ICCD costs were estimated in each trial site using a
primary costing approach to include staff, accommodation and
consumables. In PCT1 and PCT2 clinics were available only to
trial participants so all costs were included; in PCT3 the
Table 4. Odds Ratios for primary and secondary outcomes.
Odds ratio 95% confidence interval
Primary outcome (combined control) 1.56 0.983, 2.49
Secondary outcomes
HbA1c control (,= 7.0%/53 mmol/mol) 1.45 1.07, 1.96
Blood Pressure control (,140/80 mm Hg) 1.23 0.88, 1.73
Total Cholesterol (,154 mg/dl/,4 mmol/L) 1.48 1.08, 2.03
doi:10.1371/journal.pone.0093964.t004
Table 5. Odds ratio of achieving primary outcome with full regression model.
Fixed effects Estimate SE p-value Odds ratio 95% CI
Intervention arm 0.447 0.237 0.059 1.56 0.983, 2.49
Controlled at baseline 2.26 0.216 ,2610216 9.61 6.29, 14.7
Male 20.113 0.196 0.564 0.893 0.609, 1.31
Age at baseline 0.002 0.010 0.869 1.000 0.983, 1.02
PCT Site 2 20.202 0.399 0.613 0.817 0.374, 1.79
PCT Site 3 20.420 0.286 0.143 0.657 0.375, 1.15
Deprivation index 0.003 0.008 0.710 1.000 0.988, 1.02
Smoker 20.276 0.373 0.460 0.759 0.365, 1.58
Hypertension 20.420 0.211 0.046 0.657 0.435, 0.99
IHD 20.044 0.250 0.861 0.957 0.586, 1.56
Cerebrovascular disease 0.427 0.370 0.248 1.56 0.743, 3.17
Heart failure 21.87 1.06 0.077 0.154 0.019, 1.22
Peripheral vascular disease 21.22 0.774 0.115 0.295 0.065, 1.35
Renal failure 20.130 0.498 0.794 0.878 0.331, 2.33
Asian 20.051 0.258 0.842 0.950 0.573, 1.57
Black 20.054 0.548 0.922 0.947 0.324, 2.77
Other 0.082 0.472 0.862 1.09 0.430, 2.73
doi:10.1371/journal.pone.0093964.t005
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proportion of service costs attributable to trial patients was
included in the analysis. Other NHS resource use was recorded via
patient questionnaires to include community and hospital resource
use. Unit costs per ICCD visit, overall ICCD costs per patient
referred to the service, and average total care cost per patient was
estimated. Costs were standardised to 2009/10 prices where
possible. Health related quality of life (HRQoL) was measured at
baseline and 18 months using EQ-5D. Cost-effectiveness was
assessed by comparing incremental costs and marginal benefits.
Sensitivity analysis was undertaken.
Results
Initially 51 general practices were recruited to the study, but two
dropped out prior to randomisation. 49 general practices were
randomised, 24 to the intervention (a total of 1057 patients) and 25
to the control arm (a total of 940 patients). A further three
practices withdrew prior to study commencement leaving 46
practices randomised, 23 to the intervention and 23 to the control
arm. There were 11, 13 and 22 practices in PCT 1, PCT 2 and
PCT 3 respectively. The CONSORT flow diagram of GP
practices and participants through the study is shown in Figure 2.
Attendance at ICCD
In PCTs 1 and 2, 145 (out of 431, 34%) and 35 (out of 240, 15%)
trial participants were referred and attended the ICCDs, respec-
tively. In PCT 3, the ICCDs were open to receive referrals to all the
patients from the intervention practices and not just the trial
patients. Therefore, the attendance of the trial patients in this PCT
was estimated. In total, 101 patients attended ICCDs in PCT 3. As
the proportion of the trial participation from the intervention
practices in PCT 3 was 19%, we estimated 19 of the 101 patients
attended the ICCDs were trial patients (out of 386, 5%).
Baseline Data
Intervention and control participants were broadly similar at
baseline with respect to gender, smoking status, co-morbidities,
achievement of blood pressure, HbA1c and cholesterol targets and
mean values of these variables (Table 1). There was a difference
between groups with respect to combined control (primary
outcome), with 11.2% of intervention vs. 8.7% of control patients
achieving this. (P = 0.09, unadjusted chi-squared test). There were
differences between PCTs in achievement of combined control at
baseline; 7.2%, 9.4% and 12.6% in PCTs 1, 2 and 3 respectively.
Follow up Data
Two intervention practices refused access for follow up
assessment and including these, a total of 528 patients were lost
to follow up (intervention–324; control–204). A further 189 patients
were excluded from analysis (intervention–89; control–100) due to
incomplete data. Thus, data from 68% of the control group (636/
940) and 61% of the 644/1057 intervention group were available
for final analyses (Figure 2). There was some variation in follow up
rates by PCT: 383/673 (57%) in PCT 1, 285/465 (61%) in PCT 2,
Table 6. Cost of patient consultation at ICCDs.
PCT Total costs Total consultations
Patients attending
ICCD
Average cost per
consultation
Average cost per patient
attending ICCD
1 £43,553 442 145 £98.54 £300.37
2 £8,881 120 35 £74.01 £253.74
3 (trial patients only) £14,701* 95 19 £154.75 £773.74
Total £67,135 657 199 £102.18 £337.36
*During the trial period, there were 500 consultations, each costed at £154.75. This gives a total cost of £77,375, of which 19% (£14,701) was attributed to trial patients.
doi:10.1371/journal.pone.0093964.t006
Table 7. Direct healthcare costs by resource category.
Resource item Intervention (n=665) Control (n =657) p-value
Mean SE Mean SE
Intermediate care clinic for diabetes 60.18
Cost of consultations
Primary care doctor and nurse costs 37.25 2.335 31.19 2.044 0.051
Community clinic staff 1.46 0.381 0.49 0.201 0.025
Hospital doctor and nurse costs 26.13 3.876 32.03 5.272 0.366
AE staff 1.02 0.525 0.59 0.295 0.476
Optometrist, podiatrist and dietician 11.65 1.047 12.51 0.907 0.534
Sub total 137.70 5.53 76.82 6.25 ,0.001
Cost of care
Diabetes tests 58.27 2.27 62.74 2.63 0.199
Hospital inpatient costs 155.71 75.60 98.96 58.67 0.554
Total costs 351.68 76.51 238.52 60.70 0.247
doi:10.1371/journal.pone.0093964.t007
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and 612/859 (71%) in PCT 3. Table S1 shows percentages and
numbers of patients with missing data for baseline, and similarly for
follow-up. These missing values are for the primary outcome
variable, individual secondary outcome variables, each of the
covariates used in the primary analysis and before LOCF was
applied. Baseline characteristics of those patients who were
included in the analysis are presented in Table 2. While the
descriptive characteristics were similar, there was no significant
difference between intervention and control participants in the
number of people who had ‘controlled blood pressure’ (Table 1 and
Table 2).
Primary Outcome
At follow up 14.3% of patients in the intervention group vs.
9.3% in the control group achieved combined control (Table 3).
Percentage achievement (intervention vs. control) was 13.7 vs.
11.0, 10.5 vs. 11.3 and 14.2 vs. 7.7 in PCTs 1, 2 and 3 respectively.
Of the 1280 patients observed at both baseline and follow-up, 33
were excluded from the regression analysis owing to missing data
values for one or more covariates. The odds ratio for achievement
of combined control for intervention vs. controls was 1.56 (95%CI
0.93, 2.49) (Table 4). Table 5 shows the full regression model
showing all covariates.
Secondary Outcomes
Intervention group patients were more likely to achieve control
of HbA1c and total cholesterol at follow-up (Table 4). Mean values
of individual components of combined control are shown in
Table 3. For all components, after adjustment for covariates,
differences in change were small but favoured the intervention
group and for cholesterol the difference was statistically significant
(p = 0.014). Approximate intra-class correlation coefficients were
as follows: HbA1c: 0.036, systolic blood pressure: 0.037, diastolic
blood pressure: 0.051, cholesterol: 0.061.
Economic Results
The unit cost per ICCD consultation is shown in Table 6. The
mean cost of an ICCD consultation was £102.18 (range £74.01–
£154.75). The overall cost of ICCD visits per patient referred to
the service was £337.36 (range £253.74–£773.74).
Other direct healthcare costs for patients in the two trial groups
are shown in Table 7. These figures are based on 1322 patients
reporting resource use. Analysis of community consultations
indicates that the mean primary care (GP and practice nurse
visits) cost per patient was slightly higher in the ICCD group
(£37.25 vs. £31.19, p = 0.051); community clinic costs were
significantly higher (£1.46 vs. £ 0.49, p = 0.025); differences in
other costs were not significant. Overall, total consultation costs
(including ICCD visits) were significantly higher in the interven-
tion group; £137.70 (SE=£5.53) vs. £76.82 (SE=£6.25), p,
0.001). The total cost of care per patient (including diagnostic tests
and hospital inpatient stay) was higher in the intervention group
(£351.68 vs. £238.52), but this difference did not reach statistical
significance (p = 0.247).
There was no significant difference in HRQoL between patient
groups at baseline (Table 8). An incremental cost-effectiveness
ratio (ICER) of +£7,778 per QALY gained, following 1,000
replicated bootstraps, indicated that ICCD was marginally more
expensive at producing health gain (EQ-5D) for patients.
Discussion
Our results show that providing practices with access to an
ICCD service led to an increase in the proportion of patients
achieving targets for control as assessed by our primary outcome
measure (control of HbA1c, BP and cholesterol), although this just
failed to reach statistical significance. With adjustment for the
effects of clustering and potential confounding, the odds ratio for
achieving the combined control was 1.56 (95% CI 0.98, 2.49).
Results from the individual components of the outcome measure
showed the intervention had a significant effect on achieving
control of HbA1c and cholesterol, with less impact on blood
pressure. The effect of the intervention on mean values of HbA1c,
BP and cholesterol was modest. This achieved statistical signifi-
cance only for cholesterol, but the mean decrease of 0.20 mmol/l
in the intervention group compared with a decrease of
0.15 mmol/l in the control group is unlikely to be of clinical
importance. However this is against a background of good levels of
control of these factors in both groups at baseline, and other
studies of service interventions have also shown only modest effects
[22,25].
Taken together, these findings suggest that the intervention was
beneficial in effecting small changes in risk factors that enabled
patients to cross the threshold between adequate and inadequate
control. The proportion of trial participants attending ICCD
varied across PCTs, perhaps reflecting differences in ‘‘case
finding’’. In PCTs 1 and 2, an active ‘‘case finding’’ approach
was used in which members of the ICCD team searched GP
records to identify those with suboptimal risk factor control who
may benefit from referral. Although the ICCD service in PCT 3
visited practices to promote the clinics, it relied on primary care
practitioners identifying suitable patients for referral. As well as the
services being newly established, their introduction in the context
of a trial could also have reduced uptake. The small changes in risk
factor control may reflect low referral to ICCDs, which could have
been improved by more active case management. ICCDs are one
way to provide such an enhanced case management service in the
community with specialist input. Integrated case management
through ‘‘case finding’’ coupled with intensive intervention within
existing primary care services and settings might be equally
effective.
The remit of all ICCD services included education and up-
skilling of primary care practitioners, and so it is likely that their
impact extended beyond improving control in patients referred,
for example by offering informal advice about patients without an
Table 8. Health related quality of life by EQ-5D.
Intervention (n =289) Control (n =262) p-value
Mean (SE) Mean (SE)
Baseline 0.69 (0.02) 0.7 (0.02) 0.575
Follow-up 0.7 (0.02) 0.7 (0.02) 0.982
doi:10.1371/journal.pone.0093964.t008
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actual referral. Other studies have identified the key problem of
clinical inertia in primary care (a reluctance to step up treatment)
as a barrier to improving diabetes care [26,27]. It is likely that the
ICCD service tackled this problem, both through direct work with
patients and practice education. In addition, our qualitative study,
to be reported separately, suggested both patients and primary
care practitioners welcomed such enhanced service in the
community, a finding consistent with other studies [28,29].
Case management and workforce changes have both been
identified recently as key components of effective diabetes care
interventions [6]. Whilst the ICCDs are not explicitly constructed
around these principles, the proactive ‘‘case finding’’ approach
used in 2 and use of multi disciplinary teams in all 3 PCTs both
represent first steps towards such strategies. Although this study
was based in and focused only on the UK, the ICCDs might
present a unique opportunity for any purchaser-provider model
throughout the world. Indeed, if set up specific to the needs, such
integrated, multi-disciplinary care teams might be more effective
in other health care systems.
The economic analysis suggested that ICCD is cost neutral;
increasing costs in primary care but having no significant effect on
overall total cost per practice patient. However, this finding must
be interpreted with caution because of the skewed nature of
secondary care costs, the major cost driver. Sensitivity analysis
indicated that the overall cost of diabetes care is highly dependent
upon the inpatient costs of a small number of relatively expensive
patients. During the trial existing facilities and staff were used.
Additional start-up costs would be required if a new service were
commissioned.
Strengths and Weaknesses
The study was an ambitious attempt to evaluate an innovation
in service provision that was being widely adopted, but for which
there was no strong evidence of clinical or cost effectiveness. It is
the only public-funded, randomised trial to-date, which succeeded
in recruiting a large number of practices. These practices agreed to
be randomised, and worked closely with three ICCD services
during the trial period. It has provided the most robust evidence
to-date on the effectiveness of this intervention. The main
limitations of the trial were the low number of participants and
higher than expected loss to follow up; although in a cluster
randomised trial a reduction in size of cluster has less effect on
power than a reduction of clusters, the study had less power than
planned. The low participation rate as well as the variation in
baseline characteristics between the groups may have introduced
selection bias. In planning the study, we anticipated collection of
follow-up data for around 70% of baseline participants. We
achieved follow-up for 64% of patients, but with a significant
excess of control compared to intervention patients, contributed to
by two intervention practices dropping out of follow-up data
collection. This is a known danger of cluster randomised
controlled trials where practices (clusters) act as gatekeepers to
patients and may decide to withdraw co-operation for pragmatic
reasons, thus removing groups rather than individual participants
who may be willing to continue.
Conclusions
Our findings support the consideration of ICCD in the range of
services commissioned to provide care for people with diabetes.
This is especially relevant in the UK with the current change in
NHS commissioning, with an emphasis on ‘‘personalised,
integrated community based care’’. We have also shown the
importance of working closely with local practices to promote the
service and that without a ‘‘case finding’’ approach such services
may be under-utilised. Such integrated diabetes service in a ‘‘hub
and spoke’’ model between primary and specialist services could
utilise the specialist expertise economically and provide opportu-
nity for regular ‘‘up skilling’’ the knowledge of primary care
practitioners. This model can be easily implemented across the
world and we speculate that a structured, pre-defined and
proactive ‘‘case finding’’ approach can improve the quality of
care, reduce cardiovascular mortality without increasing the
overall cost.
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